December 1999 – The CenterWatch Monthly : PDF
Introducing the Newest CROs: Advertising Agencies
Large and diversified, gloabal agencies have entered the CRO market. IPG purchased privately held International Pharmaceutical Research, a $10 million CRO. Omnicom has taken a $20 million minority stake in Scirex
Agencies are backward integrating into drug discovery and development in order to offer a broader range of health care services to pharmaceutical companies. Other agencies are expected to follow
Independent Site Alliances Fight Back
The decline of the traditional affiliation model SMO, combined with the need of sponsors and CROs to identify top performing sites, has created an opportunity for independent site alliances.
ISAs hope to offer lower costs, high performance and quality along with more direct interaction with clinical study staff. One of their largest long-term challenges is bringing and keeping top sites in their membership.
Also in this issue:
- CenterStage Europe: No Advertising for Patients in Europe? Not True!
- Eye-On: Alzheimer's Disease